BioCentury
ARTICLE | Company News

Alizyme, Norgine deal

October 26, 2009 7:00 AM UTC

Norgine acquired Alizyme's lead compound cetilistat for £4.6 million ($7.5 million) in cash, plus undisclosed milestones and royalties. The lipase inhibitor has completed Phase II testing for obesity...